Patent Filed by Eli Lilly and Co for Novel Compounds and Imaging Formulations

According to GlobalData’s company profile on Eli Lilly and Co, Cancer treatment biomarkers was a key innovation area identified from patents. Eli Lilly and Co’s grant share as of January 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

Novel compounds and methods for pretargeted imaging formulations

The patent application US20240034722A1 discloses a series of claims related to compounds, pharmaceutical compositions, and methods for pretargeted imaging and radio-labeling biomolecules. The claims include the description of a compound of a specific formula, pharmaceutical compositions comprising the compound, and methods for pretargeted imaging and radio-labeling biomolecules using the compound. The pharmaceutical composition described in the claims does not include ascorbate or ascorbic acid, and the methods involve introducing the compound into a mammal for PET imaging after the introduction of a biologics-TCO conjugate. Additionally, the claims detail a method for radio-labeling a biomolecule by attaching a TCO-moiety to the biomolecule and reacting it with a 18F-labelled tetrazine to form a biomolecule-TCO-tetrazine-18F molecule.

The patent application outlines a comprehensive set of claims related to compounds, pharmaceutical compositions, and methods for pretargeted imaging and radio-labeling biomolecules. The claims provide specific formulas for compounds, details on pharmaceutical compositions, and step-by-step methods for pretargeted imaging and radio-labeling processes. The disclosed methods offer a novel approach to imaging and labeling biomolecules, potentially advancing the field of medical diagnostics and research. The exclusion of ascorbate or ascorbic acid in the pharmaceutical composition highlights the specificity and uniqueness of the disclosed compounds and compositions. Overall, the patent application presents a detailed and innovative contribution to the field of medical imaging and biomolecule labeling.

To know more about GlobalData’s detailed insights on Eli Lilly and Co, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies